Oxypeucedanin hydrate

CAS No. 2643-85-8

Oxypeucedanin hydrate( —— )

Catalog No. M18330 CAS No. 2643-85-8

Oxypeucedanin hydrate exhibits carbohydrate metabolizing enzymes inhibitory effect.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
5MG 61 In Stock
10MG 93 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Oxypeucedanin hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Oxypeucedanin hydrate exhibits carbohydrate metabolizing enzymes inhibitory effect.
  • Description
    Oxypeucedanin hydrate has antioxidant activity. Oxypeucedanin hydrate is an antimutagenic agent. Oxypeucedanin hydrate exhibits carbohydrate metabolizing enzymes inhibitory effect.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Antioxidant
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2643-85-8
  • Formula Weight
    304.29
  • Molecular Formula
    C16H16O6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (328.63 mM)
  • SMILES
    CC(C)(C(COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Curcumin

    Curcumin is a natural phenolic compound with impressive antioxidant properties. Curcumin is recently proved to exert its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2).

  • DW71177

    DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.

  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.